Pea F - Search Results

1

Impact of a newly established expert clinical pharmacological advice programme based on therapeutic drug monitoring results in tailoring antimicrobial therapy hospital-wide in a tertiary university hospital: Findings after the first year of implementation.

Cojutti PG, Gatti M, Bonifazi F, Caramelli F, Castelli A, Cavo M, Cescon M, Corvaglia LT, Lanari M, Marinelli S, Morelli MC, Pession A, Poggioli G, Ramirez S, Siniscalchi A, Tonetti T, Trevisani F, Zanoni A, Zinzani PL, Gibertoni C, Viale P, Pea F. Cojutti PG, et al. Among authors: pea f. Int J Antimicrob Agents. 2023 Aug;62(2):106884. doi: 10.1016/j.ijantimicag.2023.106884. Epub 2023 Jun 10. Int J Antimicrob Agents. 2023. PMID: 37302773 Free article.

2

TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients.

Pea F, Bertolissi M, Di Silvestre A, Poz D, Giordano F, Furlanut M. Pea F, et al. Int J Antimicrob Agents. 2002 Nov;20(5):326-32. doi: 10.1016/s0924-8579(02)00188-7. Int J Antimicrob Agents. 2002. PMID: 12431867 Clinical Trial.

3

Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose.

Pea F, Brollo L, Viale P, Pavan F, Furlanut M. Pea F, et al. J Antimicrob Chemother. 2003 Apr;51(4):971-5. doi: 10.1093/jac/dkg147. Epub 2003 Feb 25. J Antimicrob Chemother. 2003. PMID: 12654757

4

Antimicrobial agents in elective surgery: prophylaxis or "early therapy"?

Pea F, Viale P, Furlanut MI. Pea F, et al. J Chemother. 2003 Feb;15(1):3-11. doi: 10.1179/joc.2003.15.Supplement-2.3. J Chemother. 2003. PMID: 12678408 Review.

5

[What role for fluoroquinolones in intensive therapy?].

Viale P, Pea F. Viale P, et al. Among authors: pea f. J Chemother. 2003 Aug;15 Suppl 1:5-10. J Chemother. 2003. PMID: 14535066 Review. Italian. No abstract available.

6

What is the role of fluoroquinolones in intensive care?

Viale P, Pea F. Viale P, et al. Among authors: pea f. J Chemother. 2003 Nov;15 Suppl 3:5-10. doi: 10.1080/1120009x.2003.11782356. J Chemother. 2003. PMID: 14708959 Review.

7

Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages.

Pea F, Viale P, Candoni A, Pavan F, Pagani L, Damiani D, Casini M, Furlanut M. Pea F, et al. Clin Pharmacokinet. 2004;43(6):405-15. doi: 10.2165/00003088-200443060-00004. Clin Pharmacokinet. 2004. PMID: 15086277 Clinical Trial.

8

Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure.

Pea F, Viale P, Damiani D, Pavan F, Cristini F, Fanin R, Furlanut M. Pea F, et al. Antimicrob Agents Chemother. 2005 Aug;49(8):3550-3. doi: 10.1128/AAC.49.8.3550-3553.2005. Antimicrob Agents Chemother. 2005. PMID: 16048982 Free PMC article.

9

Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.

Pea F, Viale P, Furlanut M. Pea F, et al. Clin Pharmacokinet. 2005;44(10):1009-34. doi: 10.2165/00003088-200544100-00002. Clin Pharmacokinet. 2005. PMID: 16176116 Review.

10

Pharmacokinetic-pharmacodynamic aspects of antimicrobial prophylaxis with teicoplanin in patients undergoing major vascular surgery.

Pea F, Furlanut M, Stellini R, Bonardelli S, Signorini L, Pavan F, Matheis A, Portolani N, Lorenzotti S, Giulini SM, Viale P, Carosi G. Pea F, et al. Int J Antimicrob Agents. 2006 Jan;27(1):15-9. doi: 10.1016/j.ijantimicag.2005.09.009. Epub 2005 Dec 15. Int J Antimicrob Agents. 2006. PMID: 16343858 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

309 results

Search Page

Filters